AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05 Setembro 2023 - 10:05AM
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM” or the “Company”) today announced that
Thomas K. Equels, Chief Executive Officer of AIM, will present at
the H.C. Wainwright 25th Annual Global Investment Conference being
held September 11-13, 2023 in New York, NY and virtually.
In addition to the presentation, management will
be available to participate in virtual one-on-one meetings with
qualified members of the investor community who are registered to
attend the conference. For more information about the conference,
please visit the conference website.
A video webcast of the presentation will be
accessible for viewing on-demand beginning on Monday, September 11
at 7:00 AM ET for those registered for the event and will be
available on the Events page in the Investors section of the
Company’s website (aimimmuno.com). The webcast replay will be
archived for 90 days following the event.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.
For more information, please
visit aimimmuno.com and connect with the Company
on Twitter, LinkedIn, and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
AIM ImmunoTech (AMEX:AIM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024